Clinical use of amyloid‐positron emission tomography neuroimaging: Practical and bioethical considerations-Reference-Cited by-同舟云学术

Clinical use of amyloid‐positron emission tomography neuroimaging: Practical and bioethical considerations

Published:2015-07-25 Issue:3 Volume:1 Page:358-367
ISSN:2352-8729
Container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
language:en
Short-container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Author:

Witte Michael M.¹,Foster Norman L.²,Fleisher Adam S.³,Williams Monique M.⁴⁵,Quaid Kimberly⁶,Wasserman Michael⁷,Hunt Gail⁸,Roberts J. Scott⁹,Rabinovici Gil D.¹⁰,Levenson James L.¹¹,Hake Ann Marie¹¹²,Hunter Craig A.¹,Van Campen Luann E.¹,Pontecorvo Michael J.¹³,Hochstetler Helen M.¹,Tabas Linda B.¹,Trzepacz Paula T.¹¹²

Affiliation:

1. Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisINUSA

2. Center for Alzheimer's Care, Imaging and ResearchDepartment of NeurologyThe Brain Institute, University of UtahSalt Lake CityUTUSA

3. Banner Alzheimer's InstitutePhoenixAZUSA

4. IPC The Hospitalist Company, Inc.St. LouisMOUSA

5. VITAS Innovative HospiceSt. LouisMOUSA

6. Indiana University Center for BioethicsIndianapolisINUSA

7. Division of Geriatric MedicineUniversity of Colorado Denver School of MedicineAuroraCOUSA

8. National Alliance for CaregivingBethesdaMDUSA

9. Department of Health Behavior and Health EducationUniversity of Michigan School of Public HealthAnn ArborMIUSA

10. Memory & Aging CenterDepartment of NeurologyUniversity of California San FranciscoSan FranciscoCAUSA

11. Department of PsychiatryVirginia Commonwealth University School of MedicineRichmondVAUSA

12. Indiana University School of MedicineIndianapolisINUSA

13. Avid RadiopharmaceuticalsPhiladelphiaPAUSA

Funder

National Institutes of Health

Avid Radiopharmaceuticals

Eli Lilly and Company

Publisher

Wiley

Subject

Psychiatry and Mental health,Clinical Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.dadm.2015.06.006

Reference59 articles.

1. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial

2. Use of Florbetapir-PET for Imaging β-Amyloid Pathology

3. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study

4. Amyloid imaging as a biomarker for cerebral beta‐amyloidosis and risk prediction for Alzheimer dementia;Klunk W.E.;Neurobiol Aging,2011

5. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association;Johnson K.A.;Alzheimers Dement,2013

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE ^® system;Annals of Clinical and Translational Neurology;2022-11-02

2. Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia;JAMA Neurology;2022-11-01

3. Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques;Neurology;2021-12-14

4. Connected speech markers of amyloid burden in primary progressive aphasia;Cortex;2021-12

5. Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for β-amyloid (1–40) and (1–42) in plasma samples;Biochemical and Biophysical Research Communications;2021-10